Free Trial
→ Your Social Security check is scheduled for a 22% cut (From American Alternative) (Ad)tc pixel Free GALT Stock Alerts

Galectin Therapeutics (GALT) Short Interest Ratio & Short Volume

Galectin Therapeutics logo
$3.71 +0.07 (+1.92%)
As of 10/15/2026 04:00 PM Eastern
Compare

Galectin Therapeutics Short Interest Overview

As of September 30, 2026, Galectin Therapeutics (GALT) had a short interest of 9.21 million shares sold short, representing 29.49% of the public float. This marks a -1.38% decrease in short interest since the prior report. The short interest ratio (days to cover) is 33.7, meaning it would take 33.7 days of the average trading volume of 257,500 shares to cover all short positions.

Current Short Interest
9,206,832 shares
Previous Short Interest
9,335,305 shares
Change Vs. Previous Month
-1.38%
Dollar Volume Sold Short
$35.72 million
Short Interest Ratio
33.7 Days to Cover
Last Record Date
September 30, 2026
Outstanding Shares
65,860,000 shares
Short Percent of Float
29.49%
Today's Trading Volume
119,182 shares
Average Trading Volume
257,500 shares
Today's Volume Vs. Average
46%
Short Selling Galectin Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Galectin Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

GALT Short Interest Over Time

GALT Days to Cover Over Time

GALT Percentage of Float Shorted Over Time

Galectin Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
9/30/20269,206,832 shares $35.72 million -1.4%29.5%33.66 $3.88
9/15/20269,335,305 shares $34.82 million +2.9%29.9%25.16 $3.73
8/31/20269,075,436 shares $35.85 million +0.8%29.1%33.35 $3.95
8/14/20269,002,474 shares $30.97 million +3.5%28.8%21.58 $3.44
7/31/20268,696,498 shares $25.83 million +2.4%27.9%23.63 $2.97
7/15/20268,494,056 shares $40.43 million -5.3%27.2%11.27 $4.76
6/30/20268,972,735 shares $41.63 million +14.1%28.7%4.87 $4.64
6/15/20267,866,406 shares $20.61 million +2.7%25.2%31.36 $2.62
5/29/20267,663,672 shares $19.31 million +4.1%24.6%19.71 $2.52
5/15/20267,359,773 shares $15.97 million -0.4%23.6%21.3 $2.17
4/30/20267,388,749 shares $16.77 million -1.0%23.7%24.71 $2.27
4/15/20267,462,075 shares $19.10 million +9.7%23.9%18.64 $2.56
3/31/20266,801,737 shares $18.98 million +3.6%21.8%29.29 $2.79
3/13/20266,567,660 shares $20.29 million +27.1%21.5%13.69 $3.09
2/27/20265,169,383 shares $15.40 million +1.5%16.9%26.67 $2.98
2/13/20265,093,508 shares $14.06 million +6.2%16.3%18.28 $2.76
1/30/20264,797,622 shares $13.58 million +1.0%15.7%15.18 $2.83
1/15/20264,749,085 shares $14.96 million -3.1%15.5%9.31 $3.15
12/31/20254,902,530 shares $20.39 million -17.6%16.0%5.5 $4.16
12/15/20255,950,487 shares $38.74 million -12.7%19.5%9.55 $6.51
11/28/20256,816,789 shares $44.38 million +0.9%22.3%23.08 $6.51
11/14/20256,757,137 shares $37.23 million -2.1%22.1%15.52 $5.51
10/31/20256,903,772 shares $40.11 million -17.7%22.6%19.84 $5.81
10/15/20258,390,000 shares $43.54 million +2.2%19.0%28.5 $5.19
9/30/20258,210,000 shares $34.81 million +2.0%18.6%26.7 $4.24
9/15/20258,050,000 shares $36.23 million +0.8%18.3%22.8 $4.50
8/31/20257,990,000 shares $34.20 million +0.4%18.2%12.5 $4.28
8/15/20257,960,000 shares $28.42 million +3.2%18.1%12.6 $3.57
7/31/20257,710,000 shares $28.06 million +0.1%17.8%12.4 $3.64
7/15/20257,700,000 shares $21.56 million -1.2%17.7%13.1 $2.80
6/30/20257,790,000 shares $16.44 million -13.0%17.9%13.6 $2.11
6/15/20258,950,000 shares $12.26 million +0.6%20.6%16.9 $1.37
5/31/20258,900,000 shares $11.66 million +2.7%20.4%42.6 $1.31
5/15/20258,670,000 shares $11.44 million +2.4%19.8%40.6 $1.32
4/30/20258,470,000 shares $11.60 million +1.3%19.4%35.3 $1.37
4/15/20258,360,000 shares $11.20 million +6.0%19.2%33.9 $1.34
3/31/20257,890,000 shares $9.63 million -3.2%18.1%28.4 $1.22
3/15/20258,150,000 shares $13.69 million +0.4%18.9%12.8 $1.68
2/28/20258,120,000 shares $12.75 million +5.2%18.9%11.3 $1.57
2/15/20257,720,000 shares $10.89 million -3.3%18.0%10.6 $1.41
Did you grab your copy yet? (Ad)

Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.tc pixel

Download your free copy before the new quarter's list replaces it
1/31/20257,980,000 shares $9.98 million -2.2%18.5%11.2 $1.25
1/15/20258,160,000 shares $10.44 million +1.5%18.9%11.8 $1.28
12/31/20248,040,000 shares $10.37 million -2.8%18.5%12.1 $1.29
12/15/20248,270,000 shares $17.45 million +41.1%19.0%16.7 $2.11
11/30/20245,860,000 shares $16.94 million +2.8%13.5%26.7 $2.89
11/15/20245,700,000 shares $15.79 million +3.3%13.1%40.3 $2.77
10/31/20245,520,000 shares $13.63 million +1.1%12.8%42.9 $2.47
10/15/20245,460,000 shares $14.20 million +1.5%12.6%45 $2.60
9/30/20245,380,000 shares $14.80 million +2.3%12.4%43.7 $2.75
9/15/20245,260,000 shares $15.10 million +4.0%12.2%30.9 $2.87
8/31/20245,060,000 shares $13.64 million +1.0%11.7%29.8 $2.70
8/15/20245,010,000 shares $10.97 million +6.4%11.6%30.3 $2.19
7/31/20244,710,000 shares $11.78 million +3.1%10.9%26.7 $2.50
7/15/20244,570,000 shares $10.88 million +14.0%10.7%24 $2.38
6/30/20244,010,000 shares $9.06 million +1.5%9.4%18 $2.26
6/15/20243,950,000 shares $10.35 million +3.4%9.3%20.3 $2.62
5/31/20243,820,000 shares $10.39 million +2.4%9.0%20.2 $2.72
5/15/20243,730,000 shares $11.41 million +19.6%8.8%20.4 $3.06
4/30/20243,120,000 shares $10.95 million +13.9%7.4%18.8 $3.51
4/15/20242,740,000 shares $10.71 million +21.8%6.5%18.7 $3.91
3/31/20242,250,000 shares $5.38 million +5.1%5.3%21.3 $2.39
3/15/20242,140,000 shares $4.41 million +1.9%5.1%29.4 $2.06
2/29/20242,100,000 shares $4.11 million +1.0%5.0%30.6 $1.96
2/15/20242,080,000 shares $3.64 million No Change4.9%33.3 $1.75
1/31/20242,080,000 shares $3.52 million -0.5%4.9%32.8 $1.69
1/15/20242,090,000 shares $3.85 million -1.0%5.0%34 $1.84
12/31/20232,110,000 shares $3.50 million -0.9%5.0%33.8 $1.66
12/15/20232,130,000 shares $3.41 million +1.0%5.0%33.7 $1.60
11/30/20232,110,000 shares $4.11 million +8.2%5.0%36.9 $1.95
11/15/20231,950,000 shares $3.65 million No Change4.6%37.3 $1.87
10/31/20231,950,000 shares $3.98 million +3.7%4.7%39.3 $2.04
10/15/20231,880,000 shares $3.78 million -5.5%4.5%35.9 $2.01
9/30/20231,990,000 shares $3.82 million -1.5%4.8%36.1 $1.92
9/15/20232,020,000 shares $3.56 million No Change4.8%40.3 $1.76
8/31/20232,020,000 shares $3.54 million +2.5%4.8%35.7 $1.75
8/15/20231,970,000 shares $3.15 million -3.4%4.7%32.2 $1.60
7/31/20232,040,000 shares $3.06 million -1.5%4.8%33.6 $1.50
7/15/20232,070,000 shares $3.37 million -3.3%4.9%35 $1.63
6/30/20232,140,000 shares $3.08 million +2.9%5.1%37.4 $1.44
6/15/20232,080,000 shares $3.04 million -0.5%4.9%35.4 $1.46
5/31/20232,090,000 shares $3.28 million -1.4%5.0%40.3 $1.57
5/15/20232,120,000 shares $3.48 million +0.5%5.0%29.1 $1.64
4/30/20232,110,000 shares $3.71 million No Change5.0%22.8 $1.76
4/15/20232,110,000 shares $4.24 million No Change5.0%21.6 $2.01
3/31/20232,110,000 shares $4.43 million -0.5%5.0%21.4 $2.10
3/15/20232,120,000 shares $4.03 million +5.0%5.0%18.5 $1.90
2/28/20232,020,000 shares $4.18 million No Change4.8%17.2 $2.07
2/15/20232,020,000 shares $2.91 million +3.1%4.8%20.5 $1.44
1/31/20231,960,000 shares $2.27 million -1.5%4.6%19.7 $1.16
1/15/20231,990,000 shares $2.27 million -0.5%4.7%24.8 $1.14
Elon says the ‘S’ word (Ad)

Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation.tc pixel

Watch the free presentation now to see what they revealed
12/30/20222,000,000 shares $2.26 million -1.5%4.7%22.7 $1.13
12/15/20222,030,000 shares $2.35 million +0.5%4.8%26.6 $1.16
11/30/20222,020,000 shares $2.57 million -0.5%4.8%32.8 $1.27
11/15/20222,030,000 shares $2.52 million -1.5%4.8%33.7 $1.24
10/31/20222,060,000 shares $2.84 million -3.7%4.9%33.9 $1.38
10/15/20222,140,000 shares $3.47 million +3.4%5.0%29.6 $1.62
9/30/20222,070,000 shares $3.37 million No Change4.9%29.8 $1.63
9/15/20222,070,000 shares $3.71 million -1.4%4.9%26.7 $1.79
8/31/20222,100,000 shares $3.99 million -1.4%4.9%24.9 $1.90
8/15/20222,130,000 shares $4.64 million -0.5%5.0%22.6 $2.18
7/31/20222,140,000 shares $4.84 million +0.9%5.0%21.4 $2.26
7/15/20222,120,000 shares $3.50 million -2.8%5.0%22.5 $1.65
6/30/20222,180,000 shares $2.86 million -1.8%5.1%19.7 $1.31
6/15/20222,220,000 shares $2.82 million +3.7%6.5%18.9 $1.27
5/31/20222,140,000 shares $2.76 million -1.4%5.0%18.8 $1.29
5/15/20222,170,000 shares $2.95 million -9.6%5.1%19.7 $1.36
4/30/20222,400,000 shares $3.72 million +7.6%5.6%23 $1.55
4/15/20222,230,000 shares $3.88 million +9.9%5.2%19.8 $1.74
3/31/20222,030,000 shares $3.27 million +2.5%4.8%20.1 $1.61
3/15/20221,980,000 shares $3.45 million +7.0%4.6%17.6 $1.74
2/28/20221,850,000 shares $3.46 million -5.6%4.3%14.7 $1.87
2/15/20221,960,000 shares $4.06 million -1.0%4.6%14.5 $2.07
1/31/20221,980,000 shares $3.82 million No Change4.6%12.7 $1.93
1/15/20221,980,000 shares $4.00 million +4.2%4.6%12.5 $2.02
12/31/20211,900,000 shares $3.93 million -11.6%4.4%11.8 $2.07
12/15/20212,150,000 shares $4.84 million -4.4%5.0%12.4 $2.25
11/30/20212,250,000 shares $5.92 million -1.8%5.3%11.2 $2.63
11/15/20212,290,000 shares $6.55 million +5.5%5.4%9.3 $2.86
10/29/20212,170,000 shares $6.88 million -11.4%5.1%8 $3.17

GALT Short Interest - Frequently Asked Questions

Short interest is the volume of Galectin Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 30th, investors have sold 9,206,832 shares of GALT short. 29.49% of Galectin Therapeutics' shares are currently sold short. Learn More on Galectin Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GALT shares currently have a short interest ratio of 33.7. Learn More on Galectin Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 29.49% of Galectin Therapeutics' floating shares are currently sold short.

Galectin Therapeutics saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 9,206,832 shares, a drop of 1.4% from the previous total of 9,335,305 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

29.49% of Galectin Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Galectin Therapeutics: Savara Inc. (22.39%), MeiraGTx Holdings PLC (6.74%), MannKind Corporation (8.35%), Immatics N.V. (2.79%), Cullinan Therapeutics, Inc. (12.98%), Aktis Oncology (9.07%), Rigel Pharmaceuticals, Inc. (17.24%), MoonLake Immunotherapeutics (10.55%), Kura Oncology, Inc. (17.54%), Jade Biosciences, Inc. (24.77%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($75.10 billion), Invesco QQQ ($52.12 billion), iShares Russell 2000 ETF ($25.28 billion), SPDR S&P Biotech ETF ($11.70 billion), Nebius Group N.V. ($10.54 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($9.69 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($9.22 billion), iShares 20+ Year Treasury Bond ETF ($8.80 billion), Financial Select Sector SPDR Fund ($7.65 billion), and Lumentum Holdings Inc. ($7.23 billion). View all of the most shorted stocks.

Short selling GALT is an investing strategy that aims to generate trading profit from Galectin Therapeutics as its price is falling. GALT shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Galectin Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GALT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GALT, twice per month. The most recent reporting period available is September, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like GALT:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:GALT is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 10/9/2026. FINRA publishes updated short interest twice a month.
From Our Partners
Wall Street’s giving up on this trade. I’m not.
Major banks have slashed their gold price targets - Morgan Stanley to $4450, JPMorgan to $4500 - after predict...
Traders Agency | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...
American Alternative | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Stop picking AI winners. Start collecting every Thursday
One fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...
Investors Alley | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel